Press releases

Implantica AG (publ) today announces that it will accept a contribution of EUR 117 million of assets from Peter Forsell, the founder and main shareholder, without monetary compensation, but with plans to secure the contributor’s control of the company also in the future as it grows through a share split of the class B shares.  

Implantica AG (publ) today announces that it will perform a downstream merger with its holding company, Implantica MediSwiss AG. This merger will not affect the shareholding of the existing shareholders in Implantica AG but will increase the free float for the benefit of all shareholders.

Implantica AG (publ) invites investors to a presentation of the second quarter 2021 at 15:00 CEST on August 24. The interim report for the second quarter will be published at 8:00 a.m. CEST on the same day.

Implantica AG (publ) bjuder in investerare till en presentation av delårsrapporten för andra kvartalet 2021, den 24 augusti klockan 15:00 CEST. Delårsrapporten för andra kvartalet kommer att publiceras klockan 08:00 CEST samma morgon.

Implantica AG (publ) meddelar idag att ett nytt team kommer att leda den kommersiella verksamheten i bolaget inkluderande fyra mycket erfarna försäljnings- och marknadsföringsexperter, varav två som börjar i augusti 2021. Stefan Vogt börjar som Chief Commercial Officer och har lång erfarenhet av att bygga upp stora försäljningsorganisationer. Steffen Schanz ansluter som VP Marketing and Product Management, med sin omfattande erfarenhet av marknadsföring av implantat. Gerhard Landwehr har utsetts till VP Business Development DACH och UK, med över 10 års erfarenhet från ledande positioner inom kommersialisering av anti-refluximplantat, och Henric Forsell, som VP Commercial Development, med sin djupa produktkunskap.

Implantica AG (publ) today announces that a new team will be heading up the commercial operations at the Company including four highly experienced sales and marketing professionals, two of whom are joining in August 2021. Stefan Vogt is joining as Chief Commercial Officer, having extensive experience in building large sales organisations. Steffen Schanz is joining as VP Marketing and Product Management, with his substantial implant marketing experience. Gerhard Landwehr has been appointed VP Business Development DACH and UK, with over 10 years’ experience in leading positions commercialising anti-reflux implants, and Henric Forsell, as VP Commercial Development, with his in-depth product knowledge.

Implantica AG (publ) meddelar idag att Robert Frigg lämnar styrelsen och går in i den rådgivande expertkommittén för att fokusera på att bidra till och stödja Implanticas utvecklingsprojekt som höggradig specialist inom produktutveckling.

Implantica AG (publ) today announces that Robert Frigg steps down from the board of directors and joins the advisory board in order to contribute to and support development projects.

Implantica AG (publ) today announces that Klinikum Friedrichshafen in Germany, one of the largest anti-reflux centers, has begun implementing RefluxStop™. The hospital has successfully completed several surgeries with RefluxStop™ performed by Prof. Dr. med. Lehmann and his team.

Implantica AG (publ) meddelar idag att Klinikum Friedrichshafen i Tyskland, ett av de största anti-refluxcentren, har börjat implementera RefluxStop™. Sjukhuset har framgångsrikt genomfört flertal operationer med RefluxStop™ utfört av Prof. Dr. med. Lehmann och hans team.